

# Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

## A2780-cisR

RRID:CVCL\_H745

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_H745

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_H745](https://web.expasy.org/cellosaurus/CVCL_H745)

**Proper Citation:** RRID:CVCL\_H745

**Description:** Cell line A2780-cisR is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Ovarian endometrioid adenocarcinoma

**Comments:** Population: African American.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** A2780-cisR

**Synonyms:** A2780-CISR, A2780/cisR, A2780cisR, A2780(cisR)

**Cross References:** cancercellines:CVCL\_H745, ChEMBL-Cells:ChEMBL3307508, ChEMBL-Targets:ChEMBL614023, Cosmic:688091, MetaboLights:MTBLS156, MetaboLights:MTBLS1014, PubChem\_Cell\_line:CVCL\_H745, Wikidata:Q54606563

**ID:** CVCL\_H745

**Hierarchy:** cvcl\_0134

**Record Creation Time:** 20220427T215105+0000

**Record Last Update:** 20260904T021136+0000

---

### Ratings and Alerts

No rating or validation information has been found for A2780-cisR.

No alerts have been found for A2780-cisR.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Binacchi F, et al. (2025) Ligand-Dependent DNA Binding and Cytotoxicity of Palladium(II) Complexes. Chemistry (Weinheim an der Bergstrasse, Germany), e03151.

Grishchenko N, et al. (2025) Toggle-Untoggle - a cell segmentation tool with an interactive user verification interface. Journal of cell science, 138(22).

Mann J, et al. (2024) Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. International journal of cancer.

Casazza A, et al. (2022) PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. Molecular cancer therapeutics, 21(4), 568.